KPB82 potently and selectively inhibits ACER2 and protects tumor and primary cells from doxorubicin-induced cytotoxicity
Arpita Devi, Ruijuan Xu, Szulc Zdzislaw, Ian Kim, Mohamed Salama, Krishna P. Bhabak, Christoph Arenz, Daniel Canals, Yusuf Awni Hannun, Cungui Mao
This paper identifies KPB82 as a potent and selective ACER2 inhibitor that reduces doxorubicin-induced cytotoxicity in multiple cell types.
bioRxiv · Oct 2, 2026 · PreprintBiochemistry